Mission Statement

Mucosis’s mission is to discover and develop mucosal vaccines for the prevention and treatment of infectious diseases. It is our goal to transform excellent research into novel high-value vaccines which serve patients in need of an efficacious therapy and improved patient convenience.

15.11.11 Mucosis announces new scientific advisory board
more >

17.05.11 Mucosis appoints Thomas Johnston as Chief Business Officer
more >

21.03.11 Mucosis starts clinical study with its lead product, Flugem®
more >

12.11.10 Dr. Barry Buckland joins the Mucosis supervisory board
more >

28.09.10 Mucosis B.V. and PATH sign agreement to pursue Mimopath®-based oral diarrhea vaccines
more >